Literature DB >> 28944686

Remission of chronic headache: Rates, potential predictors and the role of medication, follow-up results of the German Headache Consortium (GHC) Study.

Verena Henning1, Zaza Katsarava2,3, Mark Obermann4, Susanne Moebus1, Sara Schramm1.   

Abstract

Objectives To estimate remission rates of chronic headache (CH), focusing on potential predictors of headache remission and medication. Methods We used data from the longitudinal population-based German Headache Consortium (GHC) Study (n = 9,944, 18-65 years). Validated questionnaires were used at baseline (t0, 2003-2007, response rate: 55.2%), first follow-up after 1.87 ± 0.39 years (t1, 37.2%) and second follow-up after 3.26 ± 0.60 years (t2, 38.8%) to assess headache type and frequency, use of analgesics and anti-migraine drugs, medication overuse, education, BMI, smoking and alcohol consumption. CH was defined as ≥ 15 headache days/month at t0 over three months. Outcomes were: CH remission (<15 headache days/month at both follow-ups), CH persistence (≥ 15 headache days/month at both follow-ups); all others were considered as partially remitted. To estimate predictors of remission, univariate and multiple logistic regression were calculated. Results At baseline, 255 (2.6%) participants were identified with CH. Of these, 158 (62.0%) participants responded at both follow-ups. Remission was observed in 58.2% of participants, partial remission in 17.7% and persistence in 24.1%. Remission was associated with female sex (adjusted odds ratio: 3.10, 95% confidence interval: 1.06-9.08) and no medication overuse (4.16, 1.45-11.94) compared to participants with persistent CH; participants with higher headache frequency at t0 were less likely to remit (0.90, 0.84-0.97). Medication, age, education, BMI, smoking and drinking showed no effects on remission. Similar results were observed for partial remission. Conclusion The majority of CH participants remitted from CH. Female sex, no overuse of pain medication and lower headache frequency were associated with remission.

Entities:  

Keywords:  Migraine; cohort study; headache frequency; longitudinal population-based study; medication overuse; tension type headache

Mesh:

Substances:

Year:  2017        PMID: 28944686     DOI: 10.1177/0333102417699180

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  5 in total

Review 1.  Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents.

Authors:  Hans-Christoph Diener; Dagny Holle; Thomas Dresler; Charly Gaul
Journal:  Dtsch Arztebl Int       Date:  2018-06-01       Impact factor: 5.594

2.  Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.

Authors:  Richard B Lipton; Stewart J Tepper; Stephen D Silberstein; David Kudrow; Messoud Ashina; Uwe Reuter; David W Dodick; Feng Zhang; Gregory A Rippon; Sunfa Cheng; Daniel D Mikol
Journal:  Cephalalgia       Date:  2020-12-03       Impact factor: 6.292

Review 3.  Role of Yoga as an Adjunct in the Management of Migraine Headache-Current Status and Future Indications.

Authors:  D Nayar; M Mahapatro; P Nayar
Journal:  Int J Yoga       Date:  2022-03-21

4.  Usual care and a self-management support programme versus usual care and a relaxation programme for people living with chronic headache disorders: a randomised controlled trial protocol (CHESS).

Authors:  Shilpa Patel; Felix Achana; Dawn Carnes; Sandra Eldridge; David R Ellard; Frances Griffiths; Kirstie Haywood; Siew Wan Hee; Dipesh Mistry; Hema Mistry; Vivien P Nichols; Stavros Petrou; Tamar Pincus; Rachel Potter; Harbinder Kaur Sandhu; Kimberley Stewart; Stephanie Taylor; Martin Underwood; Manjit Matharu
Journal:  BMJ Open       Date:  2020-04-12       Impact factor: 2.692

5.  Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6).

Authors:  Kirstie L Haywood; Felix Achana; Vivien Nichols; Gemma Pearce; Barbara Box; Lynne Muldoon; Shilpa Patel; Frances Griffiths; Kimberly Stewart; Martin Underwood; Manjit M Matharu
Journal:  Cephalalgia       Date:  2021-05-04       Impact factor: 6.292

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.